Summary

Decentralized Clinical Trials Market Size and Growth

Decentralized Clinical Trials Market reached US$ 9.74 billion in 2025 and is expected to reach US$ 34.13 billion by 2035, growing with a CAGR of 13.36% during the forecast period 2026-2035.

The Decentralized Clinical Trials Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

A Decentralized Clinical Trials Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

By Trial Model
- Fully Decentralized Trials*
- Hybrid Decentralized Trials
- Site Based Trials with Remote Components

By Phase
- Phase I*
- Phase II
- Phase III
- Phase IV

By Service
- Telemedicine and Virtual Visits*
- eConsent
- Remote Patient Monitoring
- Home Healthcare
- Direct to Patient Supply
- Data Management and Analytics
- Patient Recruitment and Engagement
- Regulatory and Compliance Support

By Technology
- eClinical Platforms*
- Telehealth Platforms
- eConsent Platforms
- eCOA Platforms
- Wearables and Biosensors
- Mobile Health Applications
- Data Integration and Analytics Platforms

By Therapeutic Area
- Oncology*
- Cardiovascular Diseases
- Neurology
- Infectious Diseases
- Rare Diseases

By End-User
- Pharmaceutical Companies*
- Biotechnology Companies
- CROs
- Academic and Research Institutes
- Medical Device Companies

Regional Analysis for Decentralized Clinical Trials Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

This Report Covers:
✔ Go-to-market Strategy.
✔ Neutral perspective on the market performance.
✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
✔Customized regional/country reports as per request and country level analysis.
✔ Potential & niche segments and regions exhibiting promising growth covered.
✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Research Process:
Both primary and secondary data sources have been used in the global Decentralized Clinical Trials Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Data
1.1.1. Secondary Data
1.1.2. Primary Data
1.1.3. CAGR Analysis
1.2. Market Size Estimation Methodology
1.2.1. Bottom-Up Approach
1.2.2. Top-Down Approach
1.3. Market Breakdown & Data Triangulation
1.4. Research Assumptions
1.5. Limitations
2. Definition and Overview
2.1. Study Objectives
2.2. Market Definition
2.3. Market Scope
2.4. Stakeholder Analysis
2.5. Currency Considered
2.6. Study Period
3. Executive Summary
3.1. Key Takeaways
3.2. Top To Bottom Analysis
3.3. Market Share Analysis
3.4. Data Points from Key Primary Interviews
3.5. Data Points from Key Secondary Databases
3.6. Market Snapshot
3.7. Geographical Snapshot
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing regulatory acceptance of decentralized elements
4.1.1.2. Rising demand for patient-centric trial models
4.1.1.3. Expansion of digital health technologies in clinical development
4.1.2. Restraints
4.1.2.1. Complex regulatory and operational variability across regions
4.1.2.2. Digital access and participant technology barriers
4.1.3. Impact Analysis - Drivers and Restraints
4.1.4. Opportunity
4.1.4.1. AI and advanced analytics integration
4.1.4.2. Higher adoption in hybrid trial models
4.1.5. Trends
4.1.5.1. Shift from fully virtual trials toward fit-for-purpose hybrid designs
4.1.5.2. Increased use of digital biomarkers and remote endpoint
4.1.6. Challenges
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Political Factors
5.3. Social Factors
5.3.1. Rising patient preference for remote and home-based trial participation
5.3.2. Increasing awareness and acceptance of digital health technologies
5.3.3. Growing demand for inclusive and diverse clinical trial participation
5.4. Economic Factors
5.4.1. Increasing R&D expenditure by pharmaceutical and biotechnology companies
5.4.2. Cost optimization through reduced site dependency and improved trial efficiency
5.4.3. Investments in digital health infrastructure and decentralized trial platforms
5.5. Geopolitical Factors
5.6. Supply/Value Chain Analysis
5.7. Pricing Analysis
5.8. Regulatory Analysis
5.9. Technology Landscape
5.10. Innovation & R&D Trends
5.11. Sustainability and ESG Analysis
5.12. Risk Avoidance Model
5.13. Go-To-Market (GTM) Strategy
5.14. BCG Matrix
5.15. Business Models Analysis
5.16. Demand-Supply Gap
5.17. Risk Mitigation Framework
5.18. Compliance Roadmap
5.19. Strategic Implications
5.20. Emerging Opportunities
5.21. Adoption Trends
5.22. Disruption Analysis
5.23. DMI Opinion
6. By Trial Model
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Trial Model
6.1.2. Market Attractiveness Index, Trial Model
6.2. Fully Decentralized Trials*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Hybrid Decentralized Trials
6.4. Site Based Trials with Remote Components
7. By Phase
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase
7.1.2. Market Attractiveness Index, By Phase
7.2. Phase I*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Phase II
7.4. Phase III
7.5. Phase IV
8. By Service
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service
8.1.2. Market Attractiveness Index, By Service
8.2. Telemedicine and Virtual Visits*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. eConsent
8.4. Remote Patient Monitoring
8.5. Home Healthcare
8.6. Direct to Patient Supply
8.7. Data Management and Analytics
8.8. Patient Recruitment and Engagement
8.9. Regulatory and Compliance Support
9. By Technology
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.1.2. Market Attractiveness Index, By Technology
9.2. eClinical Platforms*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Telehealth Platforms
9.4. eConsent Platforms
9.5. eCOA Platforms
9.6. Wearables and Biosensors
9.7. Mobile Health Applications
9.8. Data Integration and Analytics Platforms
10. By Therapeutic Area
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
10.1.2. Market Attractiveness Index, By Therapeutic Area
10.2. Oncology*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Cardiovascular Diseases
10.4. Neurology
10.5. Infectious Diseases
10.6. Rare Diseases
11. By End-User
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.1.2. Market Attractiveness Index, By End-User
11.2. Pharmaceutical Companies*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Biotechnology Companies
11.4. CROs
11.5. Academic and Research Institutes
11.6. Medical Device Companies
12. By Region
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America*
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Trial Model
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
13. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.1. U.S.
13.1.1. Canada
13.1.1.1. Mexico
13.2. Europe
13.2.1. Germany
13.2.1.1. UK
13.2.1.2. France
13.2.1.3. Russia
13.2.1.4. Spain
13.2.1.5. Italy
13.2.1.6. Poland
13.2.1.7. Rest of Europe
13.3. Latin America
13.3.1. Brazil
13.3.1.1. Argentina
13.3.1.2. Rest of Latin America
13.4. Asia-Pacific
13.4.1. China
13.4.1.1. India
13.4.1.2. Japan
13.4.1.3. Australia
13.4.1.4. South Korea
13.4.1.5. Indonesia
13.4.1.6. Malaysia
13.4.1.7. Rest of Asia-Pacific
13.5. Middle East and Africa
13.5.1. UAE
13.5.1.1. Saudi Arabia
13.5.1.2. South Africa
13.5.1.3. Israel
13.5.1.4. Turkiye
13.5.1.5. Rest of Middle East and Africa
14. Competitive Landscape
14.1. Competitive Scenario
14.2. Market Share Analysis - Global
14.3. Market Share Analysis - North America
14.4. Market Share Analysis - Europe
14.5. Market Share Analysis - Asia-Pacific
14.6. Mergers and Acquisitions Analysis
14.7. Partner Identification Analysis
14.8. Investment & Funding Landscape
14.9. Strategic Alliances & Innovation Pipeline
15. Company Profiles
15.1. IQVIA Inc.*
15.1.1. Company Overview
15.1.2. Product Portfolio and Description
15.1.3. Revenue Analysis
15.1.4. Pricing Analysis
15.1.5. SWOT Analysis
15.1.6. Recent Developments
15.1.6.1. Major Deals
15.1.6.2. M&A
15.1.6.3. Collaboration
15.1.6.4. Acquisition
15.1.6.5. Joint Ventures
15.1.6.6. Innovations
15.1.7. Recent News
15.1.7.1. Events
15.1.7.2. Conferences
15.1.7.3. Symposiums
15.1.7.4. Webinars
16. ICON plc
16.1. Labcorp Holdings Inc.
16.2. Parexel International Corporation
16.3. Thermo Fisher Scientific Inc.
16.4. Oracle Corporation
16.5. Dassault Systèmes SE
16.6. Medable Inc.
16.7. Science 37 Holdings, Inc.
16.8. Signant Health
16.9. Syneos Health, Inc.
16.10. Medpace Holdings, Inc.
16.11. Veeva Systems Inc.
16.12. Clario
16.13. Castor
16.14. Viedoc Technologies AB
16.15. THREAD Research
16.16. Medrio, Inc.
16.17. OpenClinica, LLC
16.18. Clinion IT Services Pvt. Ltd. (LIST NOT EXHAUSTIVE )
17. Appendix
17.1. About Us and Services
17.2. Contact Us